Migraine Prevention Options After Amitriptyline Intolerance
Start with beta-blockers (propranolol 80-240 mg/day, metoprolol 50-100 mg twice daily, or timolol 20-30 mg/day) as your first-line alternative, followed by topiramate 50-100 mg/day if beta-blockers are contraindicated or ineffective. 1
First-Line Alternatives to Amitriptyline
Beta-Blockers (Preferred Initial Choice)
- Propranolol 80-160 mg/day (long-acting formulation) is the most established first-line preventive agent with the strongest evidence base 1
- Metoprolol 50-100 mg twice daily or 200 mg modified-release once daily is equally effective 1, 2
- Timolol 20-30 mg/day also has proven efficacy 1
- Contraindications to avoid: asthma, cardiac failure, Raynaud disease, atrioventricular block, and depression 1
- Common side effects include dizziness and fatigue 3
Topiramate (Alternative First-Line)
- Dosage: 50-100 mg/day orally 1
- Particularly beneficial in patients with obesity due to associated weight loss 1
- Contraindications: nephrolithiasis, pregnancy, lactation, glaucoma 1
- Start at low dose and titrate slowly to minimize side effects 1
Candesartan (Angiotensin II Receptor Blocker)
- Dosage: 16-32 mg/day orally 1
- Reasonable alternative when beta-blockers and topiramate are not tolerated 1, 2
- Contraindication: co-administration with aliskiren 1
Second-Line Options
Valproate/Divalproex Sodium
- Dosage: 500-1500 mg/day (divalproex) or 800-1500 mg/day (sodium valproate) 1
- Proven efficacy but absolutely contraindicated in women of childbearing potential 1
- Other contraindications: liver disease, thrombocytopenia 1
Other Beta-Blockers
- Atenolol 25-100 mg twice daily or bisoprolol 5-10 mg once daily are probably effective second-line options 1, 4
- Nadolol also has supporting evidence 4
Venlafaxine
- Probably effective as second-line therapy 2, 4
- May be particularly useful in patients with comorbid depression 3
Third-Line and Specialized Options
CGRP Monoclonal Antibodies
- Erenumab 70-140 mg subcutaneous monthly, fremanezumab 225 mg monthly or 675 mg quarterly, or galcanezumab 1
- Generally reserved for patients who have failed 2-3 other preventive medications due to cost and regulatory restrictions 1
- Proven beneficial even in patients who failed multiple conventional preventives including amitriptyline 5
OnabotulinumtoxinA
- Dosage: 155-195 units to 31-39 sites every 12 weeks 1
- Evidence-based for chronic migraine specifically 1
- Typically requires specialist referral 1
Treatment Algorithm
Assess contraindications and comorbidities first 1:
- Asthma/COPD → avoid beta-blockers
- Obesity → prefer topiramate
- Depression/sleep disturbances → consider venlafaxine (not amitriptyline due to intolerance)
- Cardiovascular disease → use caution with beta-blockers
- Childbearing potential → avoid valproate
Initiate at low dose and titrate gradually over 2-3 months to assess efficacy 1
Define treatment success as ≥50% reduction in monthly headache days 1, 5
If first choice fails after adequate trial (2-3 months), switch to alternative first-line agent 1, 4
Consider CGRP antibodies after failure of 2-3 conventional preventives 1
Critical Pitfalls to Avoid
- Do not use inadequate doses or insufficient trial duration (minimum 2-3 months at target dose required) 1, 2
- Avoid medication overuse (≥15 days/month for simple analgesics, ≥10 days/month for triptans) which can cause medication-overuse headache 1
- Do not prescribe valproate to women of childbearing potential - this is an absolute contraindication 1
- Screen for beta-blocker contraindications before prescribing, particularly asthma and cardiac conditions 1, 3
- Monitor for topiramate side effects including cognitive slowing, paresthesias, and kidney stones 1